Advertisement

Ga-68 Prostate-Specific Membrane Antigen PET/CT: Imaging and Clinical Perspective in Prostate Cancer

Imaging and Clinical Perspective in Prostate Cancer

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to PET Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bray F.
        • Ferlay J.
        • Soerjomataram I.
        • et al.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; 68: 394-424
        • Rowe S.P.
        • Gorin M.A.
        • Allaf M.E.
        • et al.
        PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
        Prostate Cancer Prostatic Dis. 2016; 19: 223-230
        • Kiess A.P.
        • Banerjee S.R.
        • Mease R.C.
        • et al.
        Prostate-specific membrane antigen as a target for cancer imaging and therapy.
        Q J Nucl Med Mol Imaging. 2015; 59: 241-268
        • Afshar-Oromieh A.
        • Malcher A.
        • Eder M.
        • et al.
        PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
        Eur J Nucl Med Mol Imaging. 2013; 40: 797-798
        • Vapiwala N.
        • Hofman M.S.
        • Murphy D.G.
        • et al.
        Strategies for evaluation of novel imaging in prostate cancer: putting the horse back before the cart.
        J Clin Oncol. 2019; 37: 765-769
        • Kwan T.N.
        • Spremo S.
        • Teh A.Y.M.
        • et al.
        Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer.
        Prostate Int. 2021; 9: 107-112
        • de Rooij M.
        • Hamoen E.H.
        • Futterer J.J.
        • et al.
        Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis.
        Am J Roentgenol. 2014; 202: 343-351
        • Berger I.
        • Annabattula C.
        • Lewis J.
        • et al.
        68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology.
        Prostate Cancer prostatic Dis. 2018; 21: 204-211
        • Maurer T.
        • Eiber M.
        • Schwaiger M.
        • et al.
        Current use of PSMA-PET in prostate cancer management.
        Nat Rev Urol. 2016; 13: 226-235
        • Haider M.A.
        • Brown J.
        • Yao X.
        • et al.
        Multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: an updated systematic review.
        Clin Oncol. 2021; 33 (Royal College of Radiologists (Great Britain)): e599-e612
        • Razek A.A.K.A.
        • El-Diasty T.
        • Elhendy A.
        • et al.
        Prostate imaging reporting and Data system (PI-RADS): what the radiologists need to know?.
        Clin Imaging. 2021; 79: 183-200
        • Williams C.
        • Daneshvar M.
        • Pinto P.
        • et al.
        Emerging role of multiparametric magnetic resonance imaging in identifying clinically relevant localized prostate cancer.
        Curr Opin Oncol. 2021; 33: 244-251
        • Fendler W.P.
        • Calais J.
        • Eiber M.
        • et al.
        Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial.
        JAMA Oncol. 2019; 5: 856-863
        • D’Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • et al.
        Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
        JAMA. 1998; 280: 969-974
        • Grivas N.
        • Wit E.
        • Pos F.
        • et al.
        Sentinel lymph node dissection to select clinically node-negative prostate cancer patients for pelvic radiation therapy: effect on biochemical recurrence and systemic progression.
        Int J Radiat Oncol Biol Phys. 2017; 97: 347-354
        • Mottet N.
        • Bellmunt J.
        • Bolla M.
        • et al.
        EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent.
        Eur Urol. 2017; 71: 618-629
        • Maurer T.
        • Gschwend J.E.
        • Rauscher I.
        • et al.
        Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer.
        J Urol. 2016; 195: 1436-1443
        • Briganti A.
        • Abdollah F.
        • Nini A.
        • et al.
        Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.
        Eur Urol. 2012; 61: 1132-1138
        • Hofman M.S.
        • Lawrentschuk N.
        • Francis R.J.
        • et al.
        Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
        Lancet. 2020; 395: 1208-1216
        • Franklin A.
        • Yaxley W.J.
        • Raveenthiran S.
        • et al.
        Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
        BJU Int. 2021; 127: 71-79
        • Cooperberg M.R.
        • Pasta D.J.
        • Elkin E.P.
        • et al.
        The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
        J Urol. 2005; 173: 1938-1942
        • Zacho H.D.
        • Ravn S.
        • Afshar-Oromieh A.
        • et al.
        Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy.
        EJNMMI Res. 2020; 10: 31
        • Mottet N.
        • Bellmunt J.
        • Bolla M.
        • et al.
        EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent.
        Eur Urol. 2017; 71: 618-629
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-629
        • Fanti S.
        • Goffin K.
        • Hadaschik B.A.
        • et al.
        Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer.
        Eur J Nucl Med Mol Imaging. 2021; 48: 469-476
        • Pinker K.
        • Riedl C.
        • Weber W.A.
        Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.
        Eur J Nucl Med Mol Imaging. 2017; 44: 55-66
        • Han S.
        • Woo S.
        • Kim Y.I.
        • et al.
        Concordance between response assessment using prostate-specific membrane antigen PET and serum prostate-specific antigen levels after systemic treatment in patients with metastatic castration resistant prostate cancer: a systematic review and meta-analysis.
        Diagnostics (Basel, Switzerland). 2021; 11: 663
        • Ben Jemaa A.
        • Bouraoui Y.
        • Oueslati R.
        Insight into the heterogeneity of prostate cancer through PSA-PSMA prostate clones:Mechanisms and consequences.
        Histol Histopathol. 2014; 29: 1263-1280
        • Barbosa F.G.
        • Queiroz M.A.
        • Ferraro D.A.
        • et al.
        Prostate-specific membrane antigen PET: therapy response assessment in metastatic prostate cancer.
        Radiographics. 2020; 40: 1412-1430
        • Parimi V.
        • Goyal R.
        • Poropatich K.
        • et al.
        Neuroendocrine differentiation of prostate cancer: a review.
        Am J Clin Exp Urol. 2014; 2: 273-285
        • Amling C.L.
        • Bergstralh E.J.
        • Blute M.L.
        • et al.
        Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?.
        J Urol. 2001; 165: 1146-1151
        • Cookson M.S.
        • Aus G.
        • Burnett A.L.
        • et al.
        Variation in the definition of biochemical recurrence inpatients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
        J Urol. 2007; 177: 540-1151
        • Afshar-Oromieh A.
        • Avtzi E.
        • Giesel F.L.
        • et al.
        The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
        Eur J Nucl Med Mol Imaging. 2015; 42: 197-209
        • Cornford P.
        • van den Bergh R.C.N.
        • Briers E.
        • et al.
        EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer.
        Eur Urol. 2021; 79: 263-282
        • Gandaglia G.
        • Leni R.
        • Fossati N.
        • et al.
        Prostate-specific membrane antigen imaging in clinical guidelines: European association of urology, national comprehensive cancer network, and beyond.
        Eur Urol Focus. 2021; 7: 245-249
        • Eiber M.
        • Maurer T.
        • Souvatzoglou M.
        • et al.
        Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy.
        J Nucl Med. 2015; 56: 668-674
        • Uprimny C.
        • Kroiss A.S.
        • Decristoforo C.
        • et al.
        Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.
        Eurjnucl Med Mol Imaging. 2017; 44: 765-775
        • Hruby G.
        • Eade T.
        • Kneebone A.
        • et al.
        Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer.
        Radiother Oncol. 2017; 122: 99-102
        • Thompson I.M.
        • Valicenti R.K.
        • Albertsen P.
        • et al.
        Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline.
        J Urol. 2013; 190: 441-449
        • Stephenson A.J.
        • Scardino P.T.
        • Kattan M.W.
        • et al.
        Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
        J Clin Oncol. 2007; 25: 2035-2041
        • King C.R.
        Adjuvant versus salvage radiotherapy for high-risk prostate cancer patients.
        Semin Radiat Oncol. 2013; 23: 215-221
        • King C.R.
        The dose-response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis.
        Radiother Oncol. 2016; 121: 199-203
        • Stephenson A.J.
        • Shariat S.F.
        • Zelefsky M.J.
        • et al.
        Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
        JAMA. 2004; 291: 1325-1332
        • Goenka A.
        • Magsanoc J.M.
        • Pei X.
        • et al.
        Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
        Int J Radiat Oncol Biol Phys. 2012; 84: 112-118
        • Kane C.J.
        • Amling C.L.
        • Johnstone P.A.S.
        • et al.
        Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.
        Urology. 2003; 61: 607-611
        • Heidenreich A.
        • Bastian P.J.
        • Bellmunt J.
        • et al.
        EAU guidelines on prostate cancer Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer.
        Eur Urol. 2014; 65: 467-479
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumors: revised RECIST guideline(version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Fendler W.P.
        • Weber M.
        • Iravani A.
        • et al.
        Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer.
        Clin Cancer Res : official J Am Assoc Cancer Res. 2019; 25: 7448-7454